David Eichenbaum, MD

Experts conclude this series highlighting what is on the horizon of retinal disease care.

Experts discuss challenges in integrating gene therapy and port delivery systems early in treating common retinal diseases while emphasizing historical challenges and safety considerations.

Experts continue their discussion of gene therapy, highlighting safety concerns and the need for more trials and data.

Experts shift to the prospect of gene therapy in treating retinal diseases.

Experts discuss the use of biosimilars in treating neovascular age-related macular edema (nAMD) and diabetic macular edema (DME).

Experts discuss the safety of aflibercept 8 mg, emphasizing familiarity, efficacy, and durability, supported by reassuring data from the two-year PULSAR and PHOTON studies.

Experts discuss the practice of loading doses for newer agents and when they would consider this suitable for patients.

Experts discuss the importance of fluid management, presenting a range of perspectives on managing complex cases.

Experts reflect on the current information available on the safety and durability of second-generation agents aflibercept 8 mg and faricimab.

Experts share their real-world experience with aflibercept 8 mg, comparing it to its predecessor, aflibercept 2 mg.

Experts share their real-world experience with second-generation therapies, focusing on faricimab.

Experts discuss the timing of switching agents, particularly when switching to newer agents like aflibercept 8 mg or faricimab.

Experts expand on the discussion of first-line therapy choice, discussing how insurance mandates may alter treatment paths and the importance of catering to patient goals.

Experts discuss the importance of optimizing first-line therapies in the treatment of retinal diseases like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).